Main Article Content
The pandemic of the new coronavirus infection COVID-19 and the quarantine measures that followed it, in particular, the self-isolation of the population, could seriously affect the quality of permanent pharmacotherapy (FT) and the adherence to it of patients with chronic non-communicable diseases. In patients with stable coronary artery disease during self-isolation during the COVID-19 pandemic and the associated lack of constant contact with the attending physician, a deterioration in adherence was revealed with an increase in the number of patients who stopped taking several or all prescribed drugs. The most pronounced negative dynamics was observed in adherence to disaggregants and statins. The leading barriers to adherence during the period of self-isolation were the fear of side effects of LP and unwillingness to take a large amount of LP for a long time.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Vakirlis E., Bakirtzi K., Papadimitriou I., et al. Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2020;34(11):e673-e675. DOI:10.1111/jdv.16759.
Fragoulis G.E., Evangelatos G., Arida A., et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic [published online ahead of print, 2020 May 31]. Ann Rheum Dis. 2020;annrheumdis-2020-217935. DOI:10.1136/annrheumdis-2020-217935
Kretchy I.A., Asiedu-Danso M., Kretchy J.P. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. Res Social Adm Pharm. 2020;S1551-7411(20)30332-6. DOI:10.1016/j.sapharm.2020.04.007.
Kostev K., Kumar K., Konrad M., Bohlken J. Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther. 2020;58(9):475- 481. DOI:10.5414/CP203849.
Kuster G.M., Pfister O., Burkard T. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801-3. DOI:10.1093/eurheartj/ ehaa235.
Driggin E., Madhavan M.V., Bikdeli B. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems during the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371. DOI:10.1016/j.jacc.2020.03.031.